- Signaling Pathways
- Apoptosis
- TNF Receptor
TNF Receptor
Tumor Necrosis Factor Receptor; TNFR
Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.
TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).
Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.
TNF Receptor Isoform Specific Products
-
TNF Receptor
(701)
View all products
-
TNFRSF1A/
CD120a (8)View all products
-
TNFRSF3/
CD18 (1)View all products
-
TNFRSF4
(5)
View all products
-
TNFRSF5/
CD40 (142)View all products
-
TNFRSF6/
Fas/ (2)CD95 View all products
-
TNFRSF7/
CD27 (2)View all products
-
TNFRSF8/
CD30 (3)View all products
-
TNFRSF9/
4-1BB/ (3)CD137 View all products
-
TNFRSF10B/
DR5/ (1)CD262 View all products
-
TNFRSF12A/
TWEAK (5)View all products
-
TNFRSF16/
NGF Receptor/ (1)CD271 View all products
-
TNFRSF18/
GITR/ (6)CD357 View all products
All Product Categories
-
TNF Receptor Inhibitors
(903)
View all products
-
TNF Receptor Agonists
(35)
View all products
-
TNF Receptor Antagonists
(25)
View all products
-
TNF Receptor Activators
(80)
View all products
-
TNF Receptor Modulators
(8)
View all products
-
TNF Receptor Inducers
(11)
View all products
-
TNF Receptor Controls
(4)
View all products
-
TNF Receptor Ligands
(2)
View all products
-
TNF Receptor Superfamily Proteins
(282)
View all products
-
TNF Receptor Related Products (1268)
Related Products (1268)
-
Recombinant Proteins (282)
-
Antibodies (23)
-
TNF Receptor Signaling Pathway
-
TNF Receptor Isoform Comparison
-
Elipunercept
0 ImagesCat. No.: HY-P991680CAS No.: 3037408-21-9Elipunercept is a fusion protein that combines human TNFRSF1B extracellular domain fragment (1-235) fused at the C-terminus to a human IgG1 Fc fragment. Elipunercept is an immunomodulator. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
KZR-8445 TFA
0 ImagesCat. No.: HY-P10466AKZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
IBI37G5
0 ImagesCat. No.: HY-P991464IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
sEH/AChE-IN-5
0 ImagesCat. No.: HY-183341sEH/AChE-IN-5 is a selective, orally active and brain-penetrant acetylcholinesterase (AChE) and soluble epoxide hydrolase (sEH) dual inhibitor with IC50 values of 1.7 nM and 0.7 nM. sEH/AChE-IN-5 mediates neuroprotection and anti-inflammation via reduced TNF-α, IL-1β, IL-6, iNOS. sEH/AChE-IN-5 improves Scopolamine (HY-N0296)-induced learning and memory deficits mice. sEH/AChE-IN-5 can be used for the research of Alzheimer's disease. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
TNF-α-IN-12
0 ImagesCat. No.: HY-160433CAS No.: 364039-56-5TNF-α-IN-12 is a TNF-α inhibitor with IC50 of 0.1 μM. TNF-α-IN-12 can decrease the TNF-α blood levels. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-inflammatory agent 107
0 ImagesCat. No.: HY-179502Anti-inflammatory agent 107 is an orally active anti-inflammatory agent. Anti-inflammatory agent 107 inhibits and NF-κB with a superior binding affinity of -9.4578 kcal/mol. Anti-inflammatory agent 107 reduces levels of inflammatory biomarkers (TNF-α, IL-6, INF-γ, NF-κβ, C-reactive protein and Erythrocyte Sedimentation Rate) and enhances the endogenous antioxidant defense system by elevating SOD (Superoxide Dismutase), CAT (Catalase) and GSH (Glutathione) activities. Anti-inflammatory agent 107 not induces liver toxicity and demonstrates hepatoprotective effects. Anti-inflammatory agent 107 dose-dependently ameliorates leukocyte infiltration and tissue edema. Anti-inflammatory agent 107 can be used for anti-inflammatory research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Cudraflavone B
0 ImagesCat. No.: HY-N10009CAS No.: 19275-49-1Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of COX-1 and COX-2. Cudraflavone B blocks the translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and ERK, and induced the expression of SIRT1. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
IBI356
0 ImagesCat. No.: HY-P991614IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
KZR-8445
0 ImagesCat. No.: HY-P10466CAS No.: 2377734-91-1KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Loganic acid 6′-O-β-D-glucoside
0 ImagesCat. No.: HY-N9000CAS No.: 176226-39-4Loganic acid 6′-O-β-D-glucoside, a iridoidal glucoside, is isolated from the whole plant of Gentiana rhodantha (Gentianaceae). Loganic acid 6′-O-β-D-glucoside inhibits LPS-induced NO and TNF-α production in macrophage RAW264.7 cells. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Akt/NF-κB/MAPK-IN-1
0 ImagesCat. No.: HY-149496CAS No.: 2994215-72-2Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
rel-Cleroindicin F
0 ImagesCat. No.: HY-N3602ACAS No.: 94535-01-0Synonyms: Rengyolonerel-Cleroindicin F (Rengyolone) is a cyclohexyl acetyl compound that can be isolated from the fruit of forsythia and has anti-inflammatory activity. It strongly inhibits the production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α). rel-Cleroindicin F does this by downregulating the activity of NF-κB and NF-κB kinases in RAW 264.7 cells stimulated by LPS (HY-D1056), thus inhibiting the expression of inducible nitric oxide synthase (NO Synthase) and nitric oxide production. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
JNJ-64164711
0 ImagesCat. No.: HY-P992395Synonyms: JNJ-711JNJ-64164711 (JNJ-711) is a bifunctional antibody that simultaneously targets human GITR/TNFRSF18 and FcγRIIIa. JNJ-64164711 binds to the GITR domain to activate the NF-κB signaling pathway, while binding to FcγRIIIa to support antibody-dependent cellular cytotoxicity (ADCC). JNJ-64164711 can specifically eliminate GITR-positive hematological tumor cells, activated T cells and intratumoral regulatory T cells through the ADCC mechanism, thereby significantly enhancing the body's anti-tumor immune response. JNJ-64164711 can be used in research related to non-small cell lung cancer, colorectal cancer, prostate cancer, renal cell carcinoma and hematological tumors. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CO delivery molecule 1
0 ImagesCat. No.: HY-144368CAS No.: 1972616-04-8CO delivery molecule 1 (compound 4) localizes to the endoplasmic reticulum, mitochondria, and lysosomes. Subcellular localization of CO delivery molecule 1 results in CO-induced toxicity effects. Anti-inflammatory effects of CO delivery molecule 1, as measured by TNF-α suppression, occur at the nanomolar level in the absence of CO release, and are enhanced with visible-light-induced CO release. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
XmAb-2513
0 ImagesCat. No.: HY-P991638XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Apremilast-d3
0 ImagesCat. No.: HY-12085S3CAS No.: 1258597-46-4Synonyms: CC-10004-d3Apremilast-d3 (CC-10004-d3) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
TNFR1-IN-2
0 ImagesCat. No.: HY-P11834CAS No.: 3053449-34-3TNFR1-IN-2 is a selective TNFR1 inhibitor with a Kd of 0.1 nM for hTNFR1. TNFR1-IN-1 inhibits TNFα-induced NF-κB signal transduction, with an IC50 value of 2.8 nM. TNFR1-IN-1 can be used in research related to inflammatory and immune diseases. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
PDE4-IN-10
0 ImagesCat. No.: HY-147950CAS No.: 2413564-66-4PDE4-IN-10 (compound 7a) is a potent PDE4 inhibitor, with an IC50 of 7.01 μM for PDE4B. PDE4-IN-10 shows selectivity, microsomal stability, inhibition of TNF-α and no major toxicities in vitro. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ASP1951
0 ImagesCat. No.: HY-P992315Synonyms: PTZ-522ASP1951 (PTZ-522) is a monoclonal antibody that targets GITR and is a GITR agonist. ASP1951 can be used for the research of advanced solid tumours. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
1,4-Dicaffeoylquinic acid (Standard)
0 Images1,4-Dicaffeoylquinic acid (Standard) (1,4-DCQA (Standard)) is the analytical standard of 1,4-Dicaffeoylquinic acid (HY-N0358). This product is intended for research and analytical applications. 1,4-Dicaffeoylquinic acid (1,4-DCQA) is a phenylpropanoid compound that can be isolated from Xanthii fructus and an inhibitor of xanthine oxidase (IC50: 7.36 μM). 1,4-Dicaffeoylquinic acid has anti-inflammatory activity and can inhibit the production of TNF-α induced by LPS (HY-D1056). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival.
The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis.
Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].
Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74.
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66.
Your Search Returned No Results.
Sorry. There is currently no product that acts on isoform Bcl-2, Bcl-W and Bim together.Please
try each isoform separately.